Shigeyoshi Iwamoto

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8

Changing Site Distribution of Colorectal Cancer in Japan

Hideho Takada, T Ohsawa, Shigeyoshi Iwamoto et al. · Diseases of the Colon & Rectum · 2002 · 97 citations

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

Shigeyoshi Iwamoto, Tsuyoshi Takahashi, Hiroshi Tamagawa et al. · Annals of Oncology · 2015 · 62 citations · Full text

Effects of fatty acids on liver metastasis of ACL‐15 rat colon cancer cells

Shigeyoshi Iwamoto, Hideto Senzaki, Yasuhiko Kiyozuka et al. · Nutrition and Cancer · 1998 · 55 citations

Timing of Resection for Synchronous Liver Metastases from Colorectal Cancer

Masaki Kaibori, Shigeyoshi Iwamoto, Morihiko Ishizaki et al. · Digestive Diseases and Sciences · 2010 · 46 citations

Surgical Oncology, Hepatology, Colorectal Surgery +7